In these cohorts, three loss-of-function mutations in the APOC3 gene were identified and the heterozygote carriers of these rare variants had about 39–44 % lower serum triglyceride levels, about 46 % lower apoC-III levels and a 36–40 % lower risk of CHD than non-carriers. The gene discussed is APOC3; the disease is coronary artery disorder.